Cyclo Therapeutics- Warrants (14/11/2025) Debt to Equity

As of the most recent data, CYTHW shows a debt-to-equity ratio of -0.0. That is below the Healthcare sector average of 0.28. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.28. Cyclo Therapeutics- Warrants (14/11/2025) is at -0.0, which is lower that average. That is roughly 100.7% below the sector mean. Use the comparison chart on this page to see how CYTHW stacks up against individual peers as well.

Investors watch CYTHW's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Cyclo Therapeutics- Warrants (14/11/2025)'s latest reading is -0.0. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Cyclo Therapeutics- Warrants (14/11/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently -0.0) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.28, while CYTHW is at -0.0. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.